Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carla J Greenbaum

Showing results (1-10 of 163) with videos related to

Pageof 17
Sort By:
Clinical Immunology (Orlando, Fla.)|August 8, 2002
Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trialsCarla J Greenbaum
Current Diabetes Reports|March 18, 2006
Progress, but not yet ready for clinical use: interrupting immune-mediated destruction of pancreatic beta cells in type 1 diabetesCarla J Greenbaum
Diabetes|May 1, 2021
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical CareCarla J Greenbaum
Diabetes/Metabolism Research and Reviews|July 12, 2002
Insulin resistance in type 1 diabetesCarla J Greenbaum
Diabetes Care|February 23, 2012
Dead or alive?Carla J Greenbaum
Pharmacological Research|March 16, 2015
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Sandra Lord, Carla J Greenbaum
The Journal of Clinical Endocrinology and Metabolism|August 8, 2007
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still outJennifer Bollyky, Carla J Greenbaum
Diabetes|May 28, 2011
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363Srinath Sanda, Carla J Greenbaum
F1000Research|August 14, 2020
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetesSandra Lord, Carla J Greenbaum
Nature Reviews. Endocrinology|May 18, 2023
Approval of teplizumab: implications for patientsCate Speake, Carla J Greenbaum
Pageof 17

Showing results (1-10 of 163) with videos related to

Sort By:
Pageof 17
Clinical Immunology (Orlando, Fla.)|August 8, 2002
Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trialsCarla J Greenbaum
Current Diabetes Reports|March 18, 2006
Progress, but not yet ready for clinical use: interrupting immune-mediated destruction of pancreatic beta cells in type 1 diabetesCarla J Greenbaum
Diabetes|May 1, 2021
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical CareCarla J Greenbaum
Diabetes/Metabolism Research and Reviews|July 12, 2002
Insulin resistance in type 1 diabetesCarla J Greenbaum
Diabetes Care|February 23, 2012
Dead or alive?Carla J Greenbaum
Pharmacological Research|March 16, 2015
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Sandra Lord, Carla J Greenbaum
The Journal of Clinical Endocrinology and Metabolism|August 8, 2007
Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still outJennifer Bollyky, Carla J Greenbaum
Diabetes|May 28, 2011
Comment on: Atkinson. It's time to consider changing the rules: the rationale for rethinking control groups in clinical trials aimed at reversing type 1 diabetes. Diabetes 2011;60:361-363Srinath Sanda, Carla J Greenbaum
F1000Research|August 14, 2020
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetesSandra Lord, Carla J Greenbaum
Nature Reviews. Endocrinology|May 18, 2023
Approval of teplizumab: implications for patientsCate Speake, Carla J Greenbaum
Pageof 17